Less Invasive Ventricular Enhancement™ (LIVE™)

President and Chief Executive Officer

With a 30-year career rooted in heart failure, structural heart, interventional cardiology and cardiac surgery, and proven success in fundraising, corporate strategy, market development and physician relationship-building, Jim Dillon serves as President and CEO of BioVentrix. He joined the company in April 2021, with the goal of building the company into a high-performance heart failure therapy company. Prior to joining BioVentrix, he co-founded Reprieve Cardiovascular, an innovator in therapy for acute decompensated heart failure (ADHF), and served as its CEO and as a Board Director. Under his leadership, the company completed first-in-human clinical, achieved FDA Breakthrough Therapy Designation, and secured Series A financing. Previously, he held a series of leadership positions in corporate strategy and sales at St. Jude Medical, driving market development, new technology adoption, capital/consumable sales strategies, and high-performance commercial teams. Prior to St. Jude Medical, Jim held senior executive sales and marketing positions with Abiomed, as well as, was a key contributor to several start-ups’ acquisition and exits; VNUS Medical Technologies (acquired by Covidien), Perclose (acquired by Abbott), Heart Technologies Inc. (acquired by Boston Scientific), and Devices for Vascular Intervention (acquired by Eli Lilly).

Chief Operating Officer

Steve Chartier joined BioVentrix in December 2021 as the company’s Chief Operating Officer (COO), bringing with him over 25 years of proven senior leadership experience managing global regulatory strategy, clinical development, and operations for emerging and established medical device and biotechnology companies. Before joining the Company, Mr. Chartier served as Vice President of Global Clinical Affairs at Sirtex Medical Limited, designing and executing clinical studies and clinical operations for a leading manufacturer of target liver cancer therapies. Prior to this time, he served as the CEO and President at Cardiovascular Clinical Sciences Foundation, a prominent CRO providing clinical trial management for cardiovascular studies. Previously, Mr. Chartier served as the Vice President of Regulatory, Quality and Clinical Affairs at Anika Therapeutics directing clinical development and global regulatory channels. Mr. Chartier also served as Chief Operating Officer for Infraredx, Inc. for many years leading the global regulatory, quality, manufacturing and clinical development strategy for a novel cardiac intravascular imaging technology mapping coronary artery disease.

Chief Medical Officer

Dr. Pillay joined BioVentrix in February 2019 as the company’s EU chief medical officer (CMO), bringing with him over 23 years of experience in the cardiovascular device marketplace. Dr. Pillay is responsible for worldwide medical affairs, product development, training, and proctoring of the LIVE therapy. Prior to Bioventrix, he was a master proctor for LivaNova where upon FDA approval he trained and assessed USA surgeons in inserting the Perceval suture-less aortic valve replacement. He was head of the cardiothoracic surgery department and chief surgeon at the Freeman Hospital in the UK. He went on to become Clinical Director of all Cardiothoracic services. He has held appointments in the UK, US and India as a cardiac surgeon with special interest in advanced surgical techniques. He is an expert in beating heart coronary artery bypass grafting, mini access AVR, suture less AVR, Ventricular Assist Devices and heart and lung transplantation.

He received his undergraduate and postgraduate training in South Africa. He was placed on the specialist register list of doctors in the UK under the Royal College of Surgeons of England, an honorary award in the UK for select doctors. He also represented the Society for Thoracic Surgeons as Director in the Royal College of Surgeons, perfusion science field.  

Board Chairman, BioVentrix

CEO and member of the board of directors of Axonics, Inc.

President and CEO, BioVentrix

President und CEO, Corvia Medical

Former President of the Heart Valve Division at St. Jude Medical

President, Tri-Star Management, Inc.

Taglich Brothers Investment Banking

Member of the board of directors at BioLife Solutions, Inc.

Founding partner and chairman of Richmond Brothers, Inc.

Chief Operating Officer of Axonics, Inc.

President of the Heart Failure Association of the ESC